MAIA Biotechnology, Inc.

MAIA

US5526411021

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
3.95 ^USD	+4.22%		+2.33%	+237.61%

Jun. 07	MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies	DJ
Jun. 07	MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA?s Approval of a Telomerase Inhibitor Agent Therapy	CI

MAIA Biotechnology, Inc. announced a financing transaction

May 20, 2024

MAIA Biotechnology, Inc. announced that it has entered into a share purchase agreement with an institutional investor to issue common shares on May 21, 2024.

Latest news about MAIA Biotechnology, Inc.

MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies	Jun. 07	DJ
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA?s Approval of a Telomerase Inhibitor Agent Therapy	Jun. 07	CI
Maia Biotechnology Reveals New Clinical Data Showing Thio?s Strong Efficacy in Non-Small Cell Lung Cancer	Jun. 04	CI
MAIA Biotechnology, Inc. announced a financing transaction	May. 20	CI
MAIA Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing	Apr. 26	MT
MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding	Apr. 21	CI
MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding	Mar. 24	CI
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board	Mar. 21	CI
MAIA Biotechnology, Inc. announced that it has received $2.920692 million in funding	Mar. 20	CI
MAIA Biotechnology, Inc. announced that it expects to receive $2.920692 million in funding	Mar. 10	CI
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients	Mar. 08	CI
MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC	Mar. 06	CI
MAIA Biotechnology, Inc. Appoints Remus Vezan to its Scientific Advisory Board	Feb. 27	CI
MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	Feb. 22	CI
MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer	Feb. 07	CI
Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds	Jan. 24	CI
MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024	Jan. 17	CI
Top Premarket Decliners	Jan. 12	MT
MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	Dec. 19	CI
MAIA Biotechnology Closes $4 Million Direct Offering	Nov. 17	MT
Top Midday Decliners	Nov. 15	MT
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma	Nov. 13	CI
MAIA Biotechnology Says Glioblastoma Treatment Gets Orphan-Drug Designation From US FDA	Nov. 10	MT

Chart MAIA Biotechnology, Inc.

Duration

Period

More charts

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.95 USD

Average target price

12.62 USD

Spread / Average Target

+219.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MAIA BIOTECHNOLOGY, INC.	+237.61%	86.26M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research